Xortx Therapeutics Inc XRTX

$1.10 +0.18 (19.57%)

Valuation

Market cap
1,998,000
Revenue TTM
$0
Net income TTM
$-2,660,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,595,900
Avg volume
968,952
Day's range
$0.82 – $1.20
Shares out
1,817,000
Stochastic %K
74%
Beta
0.83
Analysts
—
Price target
$70.00

Price

Company profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injur...

Show more

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
403 455 7727
Website
https://www.xortx.com
Address
3710 - 33rd Street NW, Calgary, Canada

Latest news

Stocktwits

Merlintrader Nov 14, 10:09 PM
$XRTX Nov 13: Japan’s patent office issued a decision to grant six composition claims supporting XORTX’s XRx-101 program. Issuance still requires registration and payment; the expected patent term runs to March 15, 2041, subject to annuity fees. Not investment advice. Read more in the $XRTX stock hub: https://www.merlintrader.com/xortx-therapeutics-stock-hub/
0 replies
blues88 Nov 14, 9:12 PM
$XRTX just delist this crap davidoff so i can take the loss.
0 replies
StockScanners Nov 14, 1:16 AM
$XRTX keep watch if this holds above .91
0 replies
ABCTTradeReview_ Nov 13, 8:07 PM
$XRTX Pullback Entry: $1.07 (11/13 2:44 PM ET) Exit (expected high): $1.56 (+46%) Reason: GOLD runner pulled back 10.8% from the $1.20 high, holding above VWAP $1.05, EMA 9 over EMA 20, RSI 62, up 16% on the day. #Pullback #DayTrading Not financial advice.
0 replies
ReversalRuler Nov 13, 7:36 PM
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $PAVM $CCHH $XRTX $CIIT
0 replies
stockinvestbull Nov 13, 5:21 PM
$XRTX lets go
0 replies
focafoca99 Nov 13, 5:20 PM
$XRTX gained a Japanese patent for its XRx-101 program.
0 replies
taxidriver514 Nov 13, 5:18 PM
$XRTX
0 replies